Skip to content

High Fat Diet for Cardiac Metabolic Reprogramming

Cardiac Metabolic Reprogramming by a Nutritional Intervention: High Fat Diet for Heart Failure

Status
Not yet recruiting
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT06747429
Acronym
HF4HF
Enrollment
80
Registered
2024-12-24
Start date
2025-03-31
Completion date
2026-07-31
Last updated
2024-12-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hearth Failure Secondary to Non-ischemic DCM with Reduced LVEF (≤40%)

Keywords

heart failure, dilated cardiomyopathy, high-fat diet, clinical trial

Brief summary

The heart is a unique organ that performs an incessant work to pump blood throughout the body. For this massive effort, it requires a very high supply of energy. Mitochondria are small components of the cells responsible for the production of energy. To produce energy, mitochondria from cardiac cells can use fuel of different origins (fats, glucose, proteins, etc). In normal circumstances, cardiac mitochondria use preferentially fats since they are more efficient in terms of quantify of energy produced. Recent data from our consortium has demonstrated that if the cardiac mitochondria switch the primary source of fuel (from fats to glucose), this results in a poor performance of the organ, which cannot supply the whole body with enough blood. This is known as heart failure. In experimental models of heart failure, we have demonstrated that a high fat diet is able to reverse the metabolic switch and make the cardiac cells mitochondria use again fats as the primary substrate to produce energy. This translates into a recovery of heart failure. In the present project, we plan to bring this concept to the human setting and perform a pilot clinical study where patients with heart failure are put in a dietary program consisting of high fat diet. The effect of this nutritional approach will be evaluated by state-of-the-art non-invasive imaging technology.

Detailed description

Heart failure (HF) is a progressive condition in which the heart muscle is unable to pump blood effectively to meet the body's needs. It affects millions of people globally and imposes a significant burden on healthcare systems due to its high morbidity, mortality, and economic costs. As the prevalence of HF continues to rise, exploring targeted and innovative treatment strategies is becoming increasingly important. The heart sustains high energy demands and primarily relies on fatty acids as its energy source in the fasting state, with a smaller contribution from glucose. During the progression of HF, there is a shift in cardiac substrate preference toward increased glucose reliance and reduced fatty acid utilization. Initially considered a protective adaptation against oxygen deficiency and lipotoxicity, this metabolic shift led to suggestions that inhibiting fatty acid oxidation could be a therapeutic strategy for HF. However, more recent evidence indicates that enhancing fatty acid utilization through a high-fat diet may attenuate cardiac dysfunction. Animal studies have demonstrated that increasing fatty acid utilization can reverse myocardial metabolic alterations and improve cardiac function in models of progressive dilated cardiomyopathy (DCM) with reduced ejection fraction. In one study, the administration of a high-fat diet restored normal myocardial metabolism, resulting in disease regression. Similarly, research using large animal models has shown that high-fat diets can significantly improve left ventricular ejection fraction (LVEF), further supporting the potential benefits of this approach. In human studies, preliminary findings suggest that lipid-based interventions may acutely improve cardiac function in individuals with HF and reduced LVEF. However, evidence on the long-term efficacy and safety of high-fat dietary patterns in HF management remains limited. This study aims to compare the effects of a high-fat diet versus a standard diet with a conventional macronutrient composition on non-ischemic DCM with reduced LVEF. The primary objective is to evaluate and compare the impact of a high-fat diet versus a standard diet on LVEF. Secondary objectives include assessing the effects on left ventricular strain, diastolic function, and blood parameters, as well as evaluating the feasibility and degree of adherence to each dietary intervention.

Interventions

Weekly isocaloric dietary profile, with total daily energy intake distributed as follows: 70% from fats, primarily sourced from nuts, extra virgin olive oil, avocados, and animal fats from fish and cheese; protein intake of 0.8-1.2 g per kg body weight (10-20%); and the remaining calories from carbohydrates (10-20%).

OTHERStandard diet

Weekly isocaloric dietary profile, with total daily energy intake distributed as follows: 30% from fats, primarily sourced from nuts, extra virgin olive oil, avocados, and animal fats from fish and cheese; protein intake of 0.8-1.2 g per kg body weight (10-20%); and 50-60% from carbohydrates.

Sponsors

INSTITUTO DE SALUD CARLOS III (ISCIII)
CollaboratorUNKNOWN
Puerta de Hierro Majadahonda University Hospital
CollaboratorUNKNOWN
Nicole Karam, European Hospital Georges Pompidou, Paris, France
CollaboratorUNKNOWN
Carol Davila University of Medicine and Pharmacy Bucharest
CollaboratorUNKNOWN
Azienda Ospedaliero-Universitaria Careggi
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
SUPPORTIVE_CARE
Masking
SINGLE (Outcomes Assessor)

Masking description

Masking will be maintained for data analysts.

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* diagnosis with HF secondary to non-ischemic DCM with reduced LVEF (≤40%) * 18 years or older * informed consent provided

Exclusion criteria

* diagnosis of ischemic dilated cardiomyopathy * recent changes in drug treatment * significant HF impairment within the past year * uncontrolled dyslipidemia * claustrophobia * presence of a pacemaker or implantable cardiac defibrillator (ICD) * liver diseases * life expectancy less than 12 months * baseline fat intake exceeding 40% of total daily energy intake

Design outcomes

Primary

MeasureTime frameDescription
Changes in left ventricular ejection fraction (LVEF)At baseline, month 2 and month 4Changes in LVEF assessed using cardiac magnetic resonance imaging (MRI)

Secondary

MeasureTime frameDescription
Diastolic functionAt baseline, month 2 and month 4Changes in diastolic function assessed using cardiac magnetic resonance imaging (MRI)
White blood cellsAt baseline, month 2 and month 4Quantification with standard laboratory procedures
Red blood cellsAt baseline, month 2 and month 4Quantification with standard laboratory procedures
HemoglobinAt baseline, month 2 and month 4Quantification with standard laboratory procedures
PlateletsAt baseline, month 2 and month 4Quantification with standard laboratory procedures
GlucoseAt baseline, month 2 and month 4Quantification with standard laboratory procedures
HDL-cholesterolAt baseline, month 2 and month 4Quantification with standard laboratory procedures
LDL-cholesterolAt baseline, month 2 and month 4Quantification with standard laboratory procedures
Left ventricular strainAt baseline, month 2 and month 4Changes in left ventricular strain assessed using cardiac magnetic resonance imaging (MRI)
Electrolytes (sodium, potassium, calcium, magnesium)At baseline, month 2 and month 4Quantification with standard laboratory procedures
Kidney function (creatinine, urea)At baseline, month 2 and month 4Quantification with standard laboratory procedures
Vitamins (vitamin B12, 25-OH Vitamin D, folate)At baseline, month 2 and month 4Quantification with standard laboratory procedures
AlbuminAt baseline, month 2 and month 4Quantification with standard laboratory procedures
Iron metabolism (iron, ferritin)At baseline, month 2 and month 4Quantification with standard laboratory procedures
Liver function (AST, ALT, γGT)At baseline, month 2 and month 4Quantification with standard laboratory procedures
C-reactive proteinAt baseline, month 2 and month 4Quantification with standard laboratory procedures
TriglyceridesAt baseline, month 2 and month 4Quantification with standard laboratory procedures

Contacts

Primary ContactFrancesco Sofi, Phd, MD
francesco.sofi@unifi.it+39 0557946519

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026